To be, or not to be immunocompetent

Critical Care

Volumn 17, Issue 5, 2013, Pages

  Volk, Hans Dieter ^a   Reinke, Petra ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR; ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 LIGAND 1;

ADAPTIVE IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; MULTIPLE ORGAN FAILURE; NOTE; PRIORITY JOURNAL; SEPSIS; SURVIVAL; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; FUNGEMIA; IMMUNOLOGY; MALE;

ANIMALS; ANTIBODIES; ANTIGENS, CD274; CTLA-4 ANTIGEN; FUNGEMIA; MALE; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84887509925     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12897     Document Type: Note

References (15)

1. Chang KC, Burnham C-A, Compton SM, Rasche DP, Mazuski R, Macdonough JS, Unsinger J, Korman AJ, Green JG, Hotchkiss RS. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care 2013, 17:R85. 10.1186/cc12711, 3706819, 23663657.
2. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995, 270:985-988. 10.1126/science.270.5238.985, 7481803.
3. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151. 10.1016/S1074-7613(00)80089-8, 10485649.
4. Sheridan C. Cautious optimism surrounds early clinical data for PD-1 blocker. Nat Biotechnol 2012, 30:729-730. 10.1038/nbt0812-729, 22871693.
5. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-1L) in the treatment of advanced human cancer. Clin Cancer Res 2013, 19:1021-1034. 10.1158/1078-0432.CCR-12-2063, 23460533.
6. Volk HD, Reinke P, Falck P, Staffer G, v Baehr R. Prognostic parameters for the clinical outcome of septic disease in immunosuppressed patients. Clin Transplant 1989, 3:246-252.
7. Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med 1997, 3:678-681. 10.1038/nm0697-678, 9176497.
8. Prass K, Meisel C, Höflich C, Braun J, Halle, Wolf H, Ruscher K, Victorov IV, Priller J, Dirnagl U, Volk HD, Meisel A. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 2003, 5:725-736.
9. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594-2605. 10.1001/jama.2011.1829, 3361243, 22187279.
10. Inoue S, Bo L, Unsinger J, Chang K, Hotchkiss RS. Dose-dependent effect of anti-CTLA4 on survival in sepsis. Shock 2011, 36:38-44. 10.1097/SHK.0b013e3182168cce, 3412306, 21368717.
11. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, Swan R, Kherouf H, Monneret G, Chung CS, Ayala A. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A 2009, 106:6303-6308. 10.1073/pnas.0809422106, 2669369, 19332785.
12. Monaghan SF, Thakkar RK, Tran ML, Huang X, Cioffi WG, Ayala A, Heffernan DS. Programmed death 1 expression as a marker for immune and physiological dysfunction in the critically ill surgical patient. Shock 2012, 38:117-122. 10.1097/SHK.0b013e31825de6a3, 22683728.
13. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 2010, 88:233-240. 10.1189/jlb.0110037, 20483923.
14. Guignant C, Lepape A, Huang X, Kherouf H, Denis L, Poitevin F, Malcus C, Chéron A, Allaouchiche B, Gueyffier F, Ayala A, Monneret G, Venet F. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunction in septic shock patients. Crit Care 2011, 15:R99. 10.1186/cc10112, 3219369, 21418617.
15. Goyert SM, Silver J. Editorial: PD-1, a new target for sepsis treatment: better late than never. J Leuk Biol 2010, 88:225-226.